CO4810374A1 - NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY - Google Patents

NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY

Info

Publication number
CO4810374A1
CO4810374A1 CO98060225A CO98060225A CO4810374A1 CO 4810374 A1 CO4810374 A1 CO 4810374A1 CO 98060225 A CO98060225 A CO 98060225A CO 98060225 A CO98060225 A CO 98060225A CO 4810374 A1 CO4810374 A1 CO 4810374A1
Authority
CO
Colombia
Prior art keywords
compounds
mammal
independently
compound
case
Prior art date
Application number
CO98060225A
Other languages
Spanish (es)
Inventor
Don E Griswold
Iv Siegfried B Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO4810374A1 publication Critical patent/CO4810374A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Abstract

Un método de tratamiento de prurito en un mamífero que necesitade ello, que comprende administrar a dicho mamífero una cantidad eficaz de un compuesto de un inhibidor de PDE4 , distinto de CP 80633. El método según la reivindicación 1, en el que el inhibidor de PDE4 es un compuesto de la fórmula: en la que: R1 y R2 , independientemente en cada caso, representan alquilo o -(CH2 )m -A; m representa cero o el número entero 1, 2 ó 3; A representa un radical hidrocarbonado cíclico no sustituido o sustituido; R3 representa un átomo de halógeno, un grupo nitro o un grupo -NR4 R5 ; R4 y R5 , independientemente en cada caso, representan hidrógeno, alquilo o alquilcarbonilo, o R4 y R5 junto con el nitrógeno al que están unidos forman un anillo heterocíclico opcionalmente sustituido; y sus sales farmacéuticamente aceptables.A method of treating pruritus in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound of a PDE4 inhibitor, other than CP 80633. The method according to claim 1, wherein the PDE4 inhibitor it is a compound of the formula: wherein: R1 and R2, independently in each case, represent alkyl or - (CH2) m -A; m represents zero or the integer 1, 2 or 3; A represents an unsubstituted or substituted cyclic hydrocarbon radical; R3 represents a halogen atom, a nitro group or a -NR4 R5 group; R4 and R5, independently in each case, represent hydrogen, alkyl or alkylcarbonyl, or R4 and R5 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring; and its pharmaceutically acceptable salts.

CO98060225A 1997-10-17 1998-10-16 NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY CO4810374A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17

Publications (1)

Publication Number Publication Date
CO4810374A1 true CO4810374A1 (en) 1999-06-30

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98060225A CO4810374A1 (en) 1997-10-17 1998-10-16 NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY

Country Status (18)

Country Link
EP (1) EP1030666A4 (en)
JP (1) JP2001520196A (en)
KR (1) KR20010031149A (en)
CN (1) CN1306426A (en)
AR (1) AR015966A1 (en)
AU (1) AU740875B2 (en)
BR (1) BR9814080A (en)
CA (1) CA2306985A1 (en)
CO (1) CO4810374A1 (en)
CZ (1) CZ20001376A3 (en)
HU (1) HUP0003792A3 (en)
IL (1) IL135581A0 (en)
NO (1) NO20001847D0 (en)
NZ (1) NZ503551A (en)
PL (1) PL341062A1 (en)
TR (1) TR200001040T2 (en)
WO (1) WO1999020280A1 (en)
ZA (1) ZA989450B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
ATE305467T1 (en) 2001-01-31 2005-10-15 Pfizer Prod Inc ETHER DERIVATIVES SUITABLE AS INHIBITORS OF PDE4 ISOZYMES
MXPA03006886A (en) 2001-01-31 2003-11-13 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes.
SK8792003A3 (en) 2001-01-31 2004-09-08 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes and pharmaceutical composition containing them
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
EP1647274A4 (en) * 2003-07-17 2008-12-10 Ono Pharmaceutical Co Remedy for pruritus comprising piperidine derivative as the active ingredient
WO2005053672A1 (en) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient
JP2005187458A (en) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd Itchiness-treating agent consisting of cilomilast or its salt as active ingredient
DK1781657T3 (en) * 2004-02-14 2013-06-10 Glaxosmithkline Ip Dev Ltd MEDICINES WITH HM74A RECEPTOR ACTIVITY
JP2008137892A (en) * 2005-03-04 2008-06-19 Eisai Co Ltd Antipruritic agent
NZ565494A (en) 2005-08-10 2011-06-30 Glaxosmithkline Llc Xanthine derivatives as selective HM74A agonists
CN101389612B (en) * 2006-02-21 2011-09-21 卫材R&D管理有限公司 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
TWI404709B (en) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4-(3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
EP2123641A4 (en) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd Crystal, amorphous form and salt of methyl n-ý3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl¨terephthalamic acid
KR20100042246A (en) 2007-08-17 2010-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Novel preparation for external use
CN102336717B (en) 2007-08-17 2013-09-18 卫材R&D管理有限公司 Quinazoline derivative
US20140121240A1 (en) 2011-06-28 2014-05-01 Maruho Co., Ltd. Novel pharmaceutical composition
MA41431B1 (en) 2015-01-30 2021-05-31 Shanton Pharma Pte Ltd Prevention or treatment of gout or uric acid disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132291T2 (en) * 1990-12-21 2000-12-14 Beecham Group Plc XANTINE DERIVATIVES
JP4141501B2 (en) * 1996-03-26 2008-08-27 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel 6-substituted phenanthridine
ES2187775T3 (en) * 1996-05-15 2003-06-16 Altana Pharma Ag IMIDAZOPIRIDINS.
AU6825898A (en) * 1997-03-07 1998-09-29 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tetrazoles
EP0998300A1 (en) * 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
ES2193539T3 (en) * 1997-06-03 2003-11-01 Altana Pharma Ag BENZONAFTIRIDINS.

Also Published As

Publication number Publication date
ZA989450B (en) 1999-04-19
CN1306426A (en) 2001-08-01
EP1030666A4 (en) 2002-10-16
WO1999020280A1 (en) 1999-04-29
JP2001520196A (en) 2001-10-30
NO20001847L (en) 2000-04-10
AU740875B2 (en) 2001-11-15
NZ503551A (en) 2002-05-31
IL135581A0 (en) 2001-05-20
EP1030666A1 (en) 2000-08-30
CZ20001376A3 (en) 2002-06-12
PL341062A1 (en) 2001-03-26
AR015966A1 (en) 2001-05-30
TR200001040T2 (en) 2001-01-22
HUP0003792A2 (en) 2001-10-28
KR20010031149A (en) 2001-04-16
HUP0003792A3 (en) 2001-12-28
AU1093899A (en) 1999-05-10
NO20001847D0 (en) 2000-04-10
CA2306985A1 (en) 1999-04-29
BR9814080A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
CO4810374A1 (en) NEW USE OF COMPOUNDS FOR ANTI-PRURITIC ACTIVITY
AR044719A1 (en) DERIVATIVES OF PHENYL AND PIRIDINYL, ITS USE, A PROCESS TO PREPARE THEM, AND MEDICATIONS CONTAINING THEM
AR010331A1 (en) COMPOUNDS DERIVED FROM 6-PHENYLPYRIDYL-2-AMINE USEFUL AS INHIBITORS US, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS OF TREATMENT USING THESE COMPOUNDS.
CO5140087A1 (en) DERIVATIVES OF 3-PHENYL-PYRIDINE YOUR SYNTHESIS PROCEDURE AND MEDICINES CONTAINING THEM
AR029614A1 (en) DERIVATIVES OF 4-PHENYL-PYRIDINE, ITS USE, A PROCESS TO PREPARE THEM, AND MEDICATIONS CONTAINING THEM
AR002746A1 (en) PIRIMIDINE-DERIVED COMPOUNDS CONDENSED WITH A HETERO-CYCLIC RING AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS.
ECSP088550A (en) NEW COMPOUNDS THAT ARE ERK INHIBITORS
AR035548A1 (en) ORGANIC COMPOUNDS
CO5050332A1 (en) FUNGICIDE COMPOSITIONS THAT INCLUDE 2-METOXIBENZOPHENONES
CO5060482A1 (en) BIARILO THERAPEUTIC DERIVATIVES
ATE152719T1 (en) CHINOLYLBENZOFURAN DERIVATIVES AS LEUCOTRIEN ANTAGONISTS
ES2039242T3 (en) A PROCEDURE FOR THE PREPARATION OF NEW PIPERIDINE DERIVATIVES.
DK1001930T3 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
CO5160347A1 (en) CARBAMIC ACID DERIVATIVES
ATE280763T1 (en) MATRIX METALLOPROTEINASE INHIBITORS
CO4920225A1 (en) 2-AMINO-6- (4-PHENOXI-2-SUBSTITUTED) -PIRIDINES SUBSTITUTED
ATE120955T1 (en) BENZYLIDENE-MALONONITRILE DERIVATIVES FOR INHIBITING PROLIFERATIVE PROCESSES IN MAMMAL CELLS.
SE0101579D0 (en) New compounds
AR045768A1 (en) CEFEM COMPOUNDS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
CO4950553A1 (en) 7-TETRAHYDROISOKINOLIN COMPOUNDS AND PROCEDURE FOR THE PREPARATION
AR012603A1 (en) PROTEASE INHIBITOR, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT; AND SYNTHESIS INTERMEDIARIES
YU46787B (en) HETEROARYL 3-OXO-PROPANE-NITRILE DERIVATIVES AND PROCESS FOR THEIR OBTAINING
AR016644A1 (en) COMPOUNDS OF 2-AMINOPIRIDINAS WITH ALCOXI RAMIFIED SUBSTITUTES, PHARMACEUTICAL COMPOSITION AND USE FOR THE MANUFACTURE OF MEDICINES
NO964698L (en) Bicyclic amine derivatives as inhibitors of nitric oxide synthetase
AR018632A1 (en) COMPOUNDS DERIVED FROM ACID 1,2,3,4-TETRAHYDROQUINOLIN-2-CARBOXILICO, ITS USE IN THE MANUFACTURE OF MEDICINES, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCESS FOR PREPARATION.